Dexpanthenol attenuates inflammatory damage and apoptosis in kidney and liver tissues of septic mice
Xi Zhao\textsuperscript{a}, Siquan Zhang\textsuperscript{a}, and Hongyi Shao\textsuperscript{b}

\textsuperscript{a}Intensive Care Unit, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China; \textsuperscript{b}Department of Emergency Intensive Care Medicine, The Central Hospital Affiliated to Shaoxing University, Shaoxing, China

ABSTRACT
Sepsis is capable of causing systemic infections resulting in multiple organ damage. Dexpanthenol (DXP) has been reported to protect against kidney and liver injury. Therefore, this paper attempts to explore the role of DXP in sepsis-induced kidney and liver injury. A mice model of sepsis was established using the cecal ligation and puncture (CLP) method. The expressions of tumor necrosis factor (TNF)-\(\alpha\), interleukin (IL)-1\(\beta\), IL-6, and monocyte chemoattractant protein (MCP)-1 in the serum of mice were measured utilizing enzyme linked immunosorbent assay (ELISA). Additionally, the damage of kidney and liver tissues in CLP-induced mice was determined by their respective commercial kits, western blot, and hematoxylin–eosin (HE) staining kits. The apoptosis of kidney and liver tissues in CLP-induced mice was assessed by means of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and western blot. It was observed that DXP decreased the expressions of TNF-\(\alpha\), IL-1\(\beta\), IL-6, and MCP-1 in the serum of CLP-induced mice, attenuated the functional impairment, pathological damage, inflammation, and cell apoptosis of kidney tissue. Meanwhile, DXP decreased the functional impairment of liver in CLP-induced mice, reduced the levels of inflammatory factors and antioxidant enzymes, attenuated liver pathological damage, and decreased cell apoptosis in liver tissues. In conclusion, DXP attenuates inflammatory damage and apoptosis in kidney and liver organs in a sepsis model.

Highlights

- Dexpanthenol protects against kidney and liver injuries in sepsis;
- Dexpanthenol suppresses inflammation and cell apoptosis of kidney in septic mice;
- Dexpanthenol alleviates liver inflammation and cell apoptosis in septic mice.

Introduction

Sepsis is an uncontrolled host response to infection, which generally lead to a life-threatening organ dysfunction [1]. Despite considerable advances in medical technology in recent years have been achieved, the incidence of sepsis continues to rise year by year [2,3]. In general, inflammatory imbalance is the initial and most critical basis for the pathogenesis of sepsis, due to the fact that the initial acute host response to an invasive pathogen usually results in phagocytosis of the pathogen by macrophages and the production of a series of pro-inflammatory cytokines [4,5]. In addition, during the process of sepsis, the elevation of apoptotic cells contribute to microvascular dysfunction and organ failure [6]. Consequently, inflammatory cytokines disorder and apoptosis...
are key factors in the pathological process of sepsis. In addition, sepsis-induced liver injury is considered as a strong independent predictor of death in the intensive care unit [7]. Meanwhile, sepsis-induced kidney injury, especially acute kidney injury, is also an important cause associated with the mortality in sepsis [8]. Therefore, seeking for effective drugs for reducing sepsis-induced kidney and liver damage is essential to overcome the high mortality of sepsis.

Dexpanthenol (DXP) is a pantothenic acid (PA) analogue that is oxidized to PA in the surrounding tissues [9]. It has been demonstrated that DXP contributes to the protection of kidney injury induced by ischemia-reperfusion in rats [10]. In addition, DXP was able to reduce cisplatin toxicity-induced liver injury and ischemia-reperfusion-induced liver injury [9,11]. The above evidence disclosed the protective role of DXP against kidney injury and liver injury. In addition, the ability of DXP to attenuate cardiovascular and respiratory damage after sepsis was observed by Kose A et al, suggesting a potential protective of DXP in sepsis [12]. However, it has not been studied whether DXP could alleviate kidney and liver injury caused by sepsis.

Therefore, the purpose of this paper is to discuss the specific effect and mechanism of DXP on kidney and liver injury after sepsis. Cecal ligation and puncture (CLP) in rodents is the most frequent way used in the animal model of sepsis. It has been regarded as the gold standard for sepsis models because these models exhibit disease patterns with typical symptoms of sepsis or septic shock, such as hypothermia, tachycardia, and shortness of breath [13]. In this study, we first established a mouse model of CLP-induced sepsis and subsequently explored the effects of DXP on the impairment of kidney and liver in septic mice. In addition, the effects of DXP on CLP-induced inflammation and apoptosis in kidney and liver tissues were also evaluated.

**Materials and methods**

**Cell culture and treatment**

Total 24 healthy Balb/c male mice (7–8-week; 18–30 g) were used for the experiments. All mice were provided by Hunan Slaughter Laboratory Animal Co. The mice were housed at a temperature of 23 ± 1°C and a relative humidity of 50 ± 10% with 12 hours of alternating lighting. During this period, mice were allowed to eat and drink freely. The experiments related to animals in this study were approved by Ethics Committee of the Central Hospital Affiliated to Shaoxing University.

To establish a CLP sepsis model, the mice were ligated at 1 cm from the end of the cecum using 3–0 wire and perforated twice with a 12-gauge pillow through the cecum [14]. Immediately after surgery, the mice were injected intraperitoneally with 0.5 ml of saline for fluid resuscitation, and the supine position was maintained. To study the effect of DXP on CLP-induced sepsis in mice, mice were randomly divided into four groups (n = 6 per group): Control group, CLP group, CLP+DXP 500 mg/kg group, and CLP+DXP 700 mg/kg group. For treatment, mice induced by CLP method were injected intraperitoneally with 500 mg/kg and 700 mg/kg of DXP immediately after surgery, respectively [10,12,15]. The same amount of water and feed was given to all groups, and the activity and feeding of all mice were observed. 24 h after surgery, kidney and liver specimens were collected for histopathological and biochemical analysis. Serum samples of mice were collected for subsequent experiments.

**Enzyme linked immunosorbent assay (ELISA) detection**

Following 24 h of CLP induction, the levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and monocyte chemoattractant protein (MCP)-1 in the serum of septic mice were assessed with the corresponding ELISA Kit (TW-reagent, Shanghai, China) in line with the standard protocols offered by the supplier.

**Western blot assay**

Frozen kidney and liver tissue samples were homogenized separately in commercial radioimmunoprecipitation assay (RIPA) lysis buffer (Elabsicence, Wuhan, China) and centrifuged 13, 200 × g for 30 min. The supernatant was collected for the determination of the protein concentration.
adopting a bicinchoninic acid assay (Solarbio Life Sciences, Beijing, China). Protein samples (30 μg) were isolated making use of 15% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes, which were then blocked with 5% skimmed milk. The membranes were subjected to incubation with primary antibodies against neutrophil gelatinase-associated lipocalin (NGAL) (Abcam, ab216462, 1:1000), kidney injury molecule (Kim)-1 (Abcam, ab78494, 1:200), TNF-α (Abcam, ab183218, 1:1000), IL-1β (Abcam, ab254360, 1:1000), IL-6 (Abcam, ab259341, 1:1000), MCP-1 (Abcam, ab25124, 1:1000), Bcl-2 (Abcam, ab182858, 1:2000), Bax (Abcam, ab32503, 1:10,000), cleaved caspase 3 (Cell Signaling Technology, #9661, 1:1000), cleaved PARP (Abcam, ab32064, 1:10,000) overnight at 4°C. After washing with TBST three times for 10 min, the membrane was incubated with a secondary antibody conjugated to horseradish peroxidase for 1 h. The visualization of protein bands was undertaken with the aid of enhanced chemiluminescence (ECL; ThermoFisher, Waltham, USA) and the images were quantified with the application of ImageJ software version 1.51 (National Institutes of Health).

**Hematoxylin-eosin (HE) staining**

The kidney and liver tissues were fixed with 4% paraformaldehyde at room temperature overnight, respectively. These tissues were embedded in paraffin and then cut into 4 μM thick slices. Next, the tissues were first stained with hematoxylin for 5 min at room temperature and then eosin for 1 min. The HE staining reagent was provided by Solarbio Life Sciences. The pathological changes of the kidney and liver tissues were observed under a light microscope (magnification × 200) [16].

**Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)**

The collected kidney and liver tissues were fixed in 10% formalin before being paraffin embedded. Subsequently, the 5-μm-thick paraffin sections were dewaxed in xylene for 10 min, then rehydrated in gradient ethanol (100, 90, 75, and 0%) for 5, 2, 2, and 2 minutes, respectively. Proteinase K without DNase (20 μg/ml) was added to the sections for 20 min at 37°C. After washing 3 times with PBS, the sections were stained with 50 μL of One Step TUNEL Apoptosis Assay Kit (Beyotime, Shanghai, China) in darkness for 1 h at 37°C and the cytoplasm was stained with DAPI. The nuclear changes and apoptosis of kidney and liver tissues were observed under a fluorescence microscope (magnification × 200; Shanghai optical instrument factory, Shanghai, China). Finally, the apoptosis rate of positive cells showing green fluorescence (wavelength: 515–565 nm) was calculated [17].

**Myeloperoxidase (MPO) activity assay**

The liver tissue was washed with cold PBS. The tissue was then homogenized and resuspended in MPO Assay Buffer (Abcam, Cambridge, MA, USA). Samples were centrifuged at 13,000 g for 10 min and the supernatant was collected. Next, 50 μL of reaction mixture was added to the liver sample and incubated at 25°C for 2 h. Subsequently, 2 μL of the stop mixture was added into the samples and incubated at room temperature for 10 min. 50 μL of LTNB reagent/standard was added into all wells and incubated for 5–10 min. The measurement of absorbance (412 nm) employed a microplate reader.

**Kidney and liver function index test**

CLP-induced mice serum was centrifuged at 3000 r/min and stored at −20°C until measurement. The serum was assayed for kidney function indicators blood urea nitrogen (BUN) and creatinine (Cre), liver function indicators glutamic-pyruvic transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP), respectively, using the corresponding commercial biochemical kits in strict accordance with the kit requirements.

**Antioxidant enzyme assay**

The expressions of antioxidant enzymes glutathione (GSH) and superoxide dismutase (SOD) in the liver tissue of CLP-induced mice were detected with the adoption of the appropriate
GSH and SOD kits (Solarbio Life Sciences) in keeping with the guidelines of the supplier.

**Statistical analysis**

All the experiment data were presented as the mean ± standard deviation (SD). Data analysis software employed GraphPad Prism 8.0 software (La Jolla, USA). The comparison among groups was implemented with the help of student t-test and one-way ANOVA followed by the Tukey’s test. The difference was taken to be statistically significant at P < 0.05.

**Results**

**DXP decreases the expressions of inflammatory cytokines in the serum of CLP-induced mice**

To identify whether the CLP-induced sepsis model was successfully established, the expressions of TNF-α, IL-1β, IL-6, and MCP-1 in the serum of mice were assayed by ELISA. Figure 1(a-d) compared the difference among the groups and found that CLP induced higher expressions of TNF-α, IL-1β, IL-6, and MCP-1 in the mice in comparison with the control group, but DXP at a concentration of 500 and 700 mg/kg greatly decreased the expressions of TNF-α, IL-1β, IL-6, and MCP-1 in the serum of CLP-induced mice. This finding indicates that the sepsis model is successfully established in mice induced by CLP method, and DXP is effective in reducing the expression of inflammatory factors in the serum of CLP-induced mice.

**DXP reduces CLP-induced damage of kidney function, inflammation, and pathological tissue in mice**

To gain insight into the impact of DXP on CLP-induced damage of kidney function in mice, we examined kidney function indicators, inflammation, and pathological tissue in our experiments. Figure 2(a,b) presented a steep increase in the expressions of BUN and Cre in the CLP group (vs Control) and a sharp decrease in the CLP+DXP 500 and 700 mg/kg groups (vs CLP). Kim1 and NGAL are considered to be the most promising markers of kidney injury [18]. Figure 2(c) showed a high level of NGAL and Kim1 in the kidney tissue of CLP-induced mice by contrast to the control group, as well as a declined level of NGAL and Kim1 in the kidney tissue of CLP-induced mice treated with DXP (500 and 700 mg/kg) in comparison with the CLP group. Additionally, the levels of inflammatory cytokines TNF-α, IL-1β, IL-6, and MCP-1 in the kidney tissues were all elevated rapidly in CLP-induced mice, but decreased after treatment with DXP at 500 and 700 mg/kg (Figure 2(d)). Moreover, on the basis of HE staining result, Figure 2(e) presented severe pathologic changes in the morphology of kidney tissue in the CLP group compared with the control group, which was restored by treatment with DXP at the concentration of 500 and 700 mg/kg. The results in this part show that DXP alleviates CLP-induced impairment in mice with respect to kidney function, inflammation, and pathological damage to kidney tissue.

**DXP reduces CLP-induced apoptosis in the kidney tissue of mice**

To assess the impact of DXP on CLP-induced apoptosis in the kidney tissue of mice, TUNEL, and western blot assays were carried out. As can be
Figure 2. DXP reduces CLP-induced damage of kidney function, inflammation and pathological tissue in mice. (a-b) Biochemical kits were used to detect the expressions of kidney function indicators BUN and Cr in the serum of mice. (c) Expressions of NGAL and Kim1 in kidney tissues was assayed adopting western blot. (d) Expressions of TNF-α, IL-1β, IL-6 and MCP-1 in kidney tissues of mice was examined applying western blot. (e) Kidney histopathological damage was observed using HE staining. ***P < 0.001 vs Control; ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 vs CLP.
seen from Figure 3(a), the apoptotic cells showing green fluorescence were markedly increased in CLP group (vs Control), while after DXP treatment, apoptotic cells gradually decreased, and fewer apoptotic cells showing green fluorescence were found in the CLP+DXP (700 mg/kg) group than those in the CLP+DXP (500 mg/kg) group. Thus, the apoptosis rate was remarkably increased by CLP but successfully decreased by DXP. More importantly, it can be seen in Figure 3(b,c) that there was a sharply decreased expression of anti-apoptotic factor Bcl-2 and elevated expressions of pro-apoptotic factor Bax, Cleaved caspase3 and cleaved PARP in the CLP+DXP (500 and 700 mg/kg) groups. Together, these findings indicate that DXP can noticeably reduce CLP-induced apoptosis in the kidney tissue of mice.

**DXP reduces CLP-induced damage of liver function, inflammation, antioxidant enzymes, and pathological tissue of mice**

To assess the influence of DXP on CLP-induced liver function in mice, we examined liver function indicators, MPO activity, the levels of inflammatory cytokines and antioxidative stress enzymes, as well as pathological tissue. It can be seen from the data in Figure 4(a-c) that the content of ALT, AST, and ALP.
in the liver of mice increased sharply under the induction of CLP (vs Control), and the indexes concentrations decreased gradually by DXP in a concentration-dependent manner. Besides, it was apparent from Figure 4(d) that there was a steep increase in the activity of MPO in CLP group and a gradual decrease in CLP+DXP (500 and 700 mg/kg) groups. In Figure 4(e), there was a clear trend of increasing levels of TNF-α, IL-1β, IL-6, and MCP-1 in the liver tissue of CLP-induced mice, as well as decreased levels of TNF-α, IL-1β, IL-6, and MCP-1 in the liver tissue of CLP-induced mice treated with DXP (500 and 700 mg/kg). In addition, we also found that the expressions of antioxidant enzymes GSH and SOD dropped by more than half in the CLP group, DXP (500 mg/kg) partially elevated the expression of GSH and SOD, while DXP (700 mg/kg) greatly raised the expression of GSH and SOD (Figure 4(f,g)). Data in Figure 4(h,i) showed that there...
were severe pathologic damages of liver tissue in the CLP group compared with the control group, which was attenuated by treatment with DXP at the concentration of 500 and 700 mg/kg. The evidence presented in this section reveal that DXP significantly improves CLP-induced damage in the liver function, liver tissue inflammation, oxidative stress, and pathological injury in mice.

**DXP reduces CLP-induced apoptosis in the hepatocytes of mice**

To find out the impact of DXP in CLP-induced apoptosis in the liver tissue of mice, the assays of TUNEL and western blot were conducted again. The data obtained from Figure 5(a) showed more TUNEL-positive cells in the CLP group (vs Control) and fewer TUNEL-positive apoptotic cells in the CLP+DXP (500 and 700 mg/kg) groups. Meanwhile, the level of Bcl-2 was declined in the CLP group but rose in the CLP+DXP (500 and 700 mg/kg) groups, while the levels of Bax, Cleaved caspase3 and Cleaved PARP showed completely opposite trends to Bcl-2 in each group. Together these studies support the notion that DXP also reduces CLP-induced apoptosis in the liver tissue of mice.

**Discussion**

Sepsis is a systemic inflammatory response or immune disorder involving the failure of multiple organs in the body [19]. Inflammatory imbalance and apoptosis are important factors in the...
pathogenesis of sepsis [20,21], and the most
damaged internal organs include kidney and liver
[22,23]. Based on these studies, this paper aims to
alleviate sepsis by ameliorating kidney and liver
injuries to determine the protective role of DXP
against kidney and liver injury in a mouse model
of sepsis.

CLP is a standard method commonly used to
induce sepsis and can trigger mice to exhibit
symptoms similar to sepsis [24]. Therefore, our
experiments used the CLP method to process mice
for establishing a sepsis model. Previous stu-
dies have shown that an imbalance of inflam-
matory cytokines is the initial symptom of sepsis,
accompanied by an overproduction of pro-
inflammatory factors TNF-α, IL-1β, IL-6 [25]. In
addition, MCP-1 is a small cytokine that belongs
to the CC chemokine family and is a biomarker for
predicting sepsis [26]. Research has indicated that
MCP-1 level in serum is notably higher in adults
who die from sepsis than in survivors [27,28]. In
our experiment, the higher expression of pro-
inflammatory factors TNF-α, IL-1β, IL-6, and che-
mokine MCP-1 in the CLP group indicated the
success of our sepsis model establishment. It is
worth noting that with the development of sepsis
diagnosis and prognosis, the biomarkers guiding
the severity and progress of sepsis are widely
researched, and more and more biomarkers have
been demonstrated to indicate sepsis or a systemic
inflammatory state, such as triggering receptor
expressed on myeloid cells-1 (TREM-1), procalsi-
tonin, and so on [29,30]; however, attributed to
a limitation in this study, we only verified more
commonly used biomarkers in the sepsis model,
and verification of other biomarkers in sepsis, as
well as exploration of the influences of potential
drugs of sepsis on these biomarkers, was deserved
to be investigated in the future work.

DXP is an alcohol analogue of pantothenic acid
(PA), formed by the penetration of panthenol into
the skin or mucous membranes, and is a com-
ponent of coenzyme A (CoA) [31]. It has
been shown that disturbances in the metabolism of
PA, taurine and phenylalanine in the kidney cortex
are associated with the development of acute kid-
ney injury in sepsis [32]. In vivo studies demon-
strated that DXP reduced the nephrotoxicity of
amikacin and the hepatotoxicity of cisplatin
[9,33]. These findings encouraged us to further
investigate the effects of DXP on kidney and liver
injury in mice model of sepsis. As expected, DXP
not only inhibited the production of pro-
inflammatory cytokines, including TNF-α, IL-1β,
IL-6, and MCP-1, in serum of septic mice, but also
reduced the protein expression of TNF-α, IL-1β,
IL-6, and MCP-1 in kidney tissues and liver tissues
of septic mice, indicating that DXP was helpful in
reducing inflammation in sepsis and sepsis-
induced kidney injury and liver injury.

NGAL is recognized as a hallmark of renal
tubular injury. It has been noted that both
mRNA and protein levels of NGAL are highly
upregulated after kidney injury following isch-
emia/reperfusion or nephrotoxicity [34,35]. Kim1
is a 38.7 kDa type I transmembrane glycoprotein,
and is expressed at low levels in the normal kidney
but its expression is sharply upregulated in a drug-
duced rodent model of acute kidney injury
(AKI) [36,37]. Thus, NGAL and Kim1 are the
main characteristic of kidney injury, and their
monitoring has significance guiding the prognosis
of kidney injury [38]. In addition, an increase in
the expressions of Cre and BUN is also considered
as the sign of kidney damage [39]. Several
researches pointed that DXP could improve the
levels of BUN and Cre in serum of rats after
kidney underwent ischemia/reperfusion [10]. In
our experiments, the expressions of BUN, Cre,
NGAL, and Kim1 were significantly elevated in
the CLP group, but decreased in a concentra-
tion-dependent manner after the addition of DXP,
suggesting that DXP exerted a protective function
against kidney injury in septic mice.

It is well established that increased levels of
ALT, AST, and ALP are associated with inflam-
amation and injury to the liver [40]. Besides, MPO
activity is closely associated with liver disease
[41]. Our experiments revealed a dramatic increase
in the expression of these molecules in the CLP
group, but a significant decrease after the addition
of DXP, suggesting an ameliorative effect of DXP
on liver function. Additionally, due to its ability to
inhibit free radical formation, DXP also plays an
important role in inhibiting oxidative stress
[42,43]. Consistently, we also observed that the
levels of antioxidant enzymes GSH and SOD,
which were reduced under CLP induction,
increased rapidly after treatment with DXP, emphasizing the protective effect of DXP against oxidative stress in liver tissue of septic mice.

Apoptosis directly contributes to microvascular dysfunction and organ failure during sepsis [6]. In our study, we found that CLP induced a high level of cell apoptosis in kidney and liver tissue. It is shown that DXP not only attenuates kidney following ischemia/reperfusion injury through inhibiting kidney cell apoptosis, but also has a protective effect against cisplatin-induced hepatotoxicity partly by decreasing the level of asymmetric dimethylarginine that induces apoptosis [9,10,44]. Similarly, our experiments also revealed that the high apoptosis level in CLP-induced kidney and liver tissues gradually decreased with the addition of DXP, demonstrating that DXP could inhibit tissue cell apoptosis so as to alleviate sepsis-induced kidney injury and liver injury.

Conclusion

Collectively, this study outlines a critical role of DXP in kidney injury and liver injury of sepsis, and DXP is able to serve as an effective therapeutic drug to attenuate inflammatory damage and apoptosis in kidney and liver organs arising from sepsis.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

All data generated or analyzed during this study are included in this article.

Ethics approval and consent to participate

This study received approval from the Ethics Committee of the Central Hospital Affiliated to Shaoxing University and the experiments were undertaken in accordance with the guidelines.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

References

[1] David S, Brunkhorst FM. [Sepsis-3: what has been confirmed in therapy?] Internist (Berl). 2017;58(12):1264–1271.
[2] Suarez De La Rica A, Gilsanz F, Maseda E. Epidemiologic trends of sepsis in western countries. Ann Transl Med. 2016;4(17):325.
[3] Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581–614.
[4] O’Leary MM, Taylor J, Eckel L. Psychopathic personality traits and cortisol response to stress: the role of sex, type of stressor, and menstrual phase. Horm Behav. 2010;58(2):250–256.
[5] D’Elia RV, Harrison K, Oyston PC, et al. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol. 2013;20(3):319–327.
[6] Cao C, Yu M, Chai Y. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis. Cell Death Dis. 2019;10(10):782.
[7] Sun J, Zhang J, Wang X, et al. Gut-liver crosstalk in sepsis-induced liver injury. Crit Care. 2020;24(1):614.
[8] Wang Z, Yang X, Qin T, et al. Efficient removal of oxytetracycline from aqueous solution by a novel magnetic clay-biochar composite using natural attapulgite and cauliflower leaves. Environ Sci Pollut Res Int. 2019;26(8):7463–7475.
[9] Bilgiç Y, Akbulut S, Aksungur Z, et al. Protective effect of dexpanthenol against cisplatin-induced hepatotoxicity. Exp Ther Med. 2018;16(5):4049–4057.
[10] Atintas R, Parlakpinar H, Beytur A, et al. Protective effect of dexpanthenol on ischemia-reperfusion-induced renal injury in rats. Kidney Blood Press Res. 2012;36(1):220–230.
[11] Aydin O, Pehlivani F, Karaca G, et al. May dexpanthenol, platelet-rich plasma, and thymoquinone provide new hope to maintain liver regeneration after partial hepatectomy? Turk J Gastroenterol. 2019;30(9):826–834.
[12] Kose A, Parlakpinar H, Ozhan O, et al. Therapeutic effects of dexpanthenol on the cardiovascular and respiratory systems following cecal ligation and puncture-induced sepsis in rats. Biotech Histochem. 2020;95(6):428–437.
[13] Rittirsch D, Huber-Lang MS, Flierl MA, et al. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009;4(1):31–36.
[14] Wang C, Yuan W, Hu A, et al. Dexmedetomidine alleviated sepsis induced myocardial ferroptosis and septic heart injury. Mol Med Rep. 2020;22(1):175–184.
[15] Li-Mei W, Jie T, Shan-He W, et al. Anti-inflammatory and anti-oxidative effects of dexpanthenol on lipopolysaccharide induced acute lung injury in mice. Inflammation. 2016;39(5):1757–1763.
[16] Xiao Z, Kong B, Fang J, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced cardiac dysfunction. Bioengineered. 2021;12(2):9367–9376.
[17] Wu Y, Zhao M, Lin Z. Pyrroloquinoline quinone (PQQ) alleviated sepsis-induced acute liver injury, inflammation, oxidative stress and cell apoptosis by downregulating CUL3 expression. Bioengineered. 2021;12(1):2459–2468.

[18] Seibert FS, Sitz M, Passfall J, et al. Prognostic value of urinary calprotectin, NGAL and KIM-1 in chronic kidney disease. Kidney Blood Press Res. 2018;43(4):1255–1262.

[19] Huang M, Cai S, Su J. The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci. 2019;20(21):5376.

[20] Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–874.

[21] Ayala A, Perl M, Venet F, et al. Apoptosis in sepsis: mechanisms, clinical impact and potential therapeutic targets. Curr Pharm Des. 2008;14(19):1853–1859.

[22] Yan J, Li S, Li S. The role of the liver in sepsis. Int Rev Immunol. 2014;33(6):498–510.

[23] Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891.

[24] Alverdy JC, Keskey R, Thewissen R. Can the cecal ligation and puncture model be repurposed to better inform therapy in human sepsis? Infect Immun. 2020;88(9):e00942–19.

[25] Hawiger J, Veach RA, Zienkiewicz J. New paradigms in sepsis: from prevention to protection of failing microcirculation. J Thromb Haemost. 2015;13(10):1743–1756.

[26] Zhu T, Liao X, Feng T, et al. Plasma monocyte chemoattractant protein 1 as a predictive marker for sepsis prognosis: a prospective cohort study. Tohoku J Exp Med. 2017;241(2):139–147.

[27] Hong TH, Chang CH, Ko WJ, et al. Biomarkers of early sepsis may be correlated with outcome. J Transl Med. 2014;12:146.

[28] Holub M, Dzupova O, Ruzkova M, et al. Selected biomarkers correlate with the origin and severity of sepsis. Mediators Inflamm. 2018;2018:7028267.

[29] Maiese A, Bolino G, Mistracchio A, et al. An immunohistochemical study of the diagnostic value of TREM-1 as marker for fatal sepsis cases. Biotech Histochem. 2019;94(3):159–166.

[30] La Russa R, Maiese A, Viola RV, et al. Searching for highly sensitive and specific biomarkers for sepsis: state-of-the-art in post-mortem diagnosis of sepsis through immunohistochemical analysis. Int J Immunopathol Pharmacol. 2019;33:2058738419855226.

[31] Thieme U, Muller K, Bergmann C, et al. Randomised trial on performance, safety and clinical benefit of hyaluronic acid, hyaluronic acid plus dexpanthenol and isotonic saline nasal sprays in patients suffering from dry nose symptoms. Auris Nasus Larynx. 2020;47(3):425–434.

[32] Ping F, Guo Y, Cao Y, et al. Metabolomics analysis of the renal cortex in rats with acute kidney injury induced by sepsis. Front Mol Biosci. 2019;6:152.

[33] Dogan EE, Erkoc R, Ekinci I, et al. Protective effect of dexpanthenol against nephrotoxic effect of amikacin: an experimental study. Biomed Pharmacother. 2017;89:1409–1414.

[34] Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534–2543.

[35] Supavekin S, Zhang W, Kucherlapati R, et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 2003;63(5):1714–1724.

[36] Amin RP, Vickers AE, Sistare F, et al. Identification of putative gene based markers of renal toxicity. Environ Health Perspect. 2004;112(4):465–479.

[37] Prozialeck WC, Vaidya VS, Liu J, et al. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int. 2007;72(8):985–993.

[38] Schrezenmeier EV, Barasch J, Budde K, et al. Biomarkers in acute kidney injury - pathophysiological basis and clinical performance. Acta Physiol (Oxf). 2017;219(3):554–572.

[39] Nogueira SAR, Oliveira SCS, Carvalho AFM, et al. Renal changes and acute kidney injury in covid-19: a systematic review. Rev Assoc Med Bras (1992). 2020;66(Suppl 2):112–7.0.

[40] Lalà V, Goyal A, Bansal P, et al. Liver function tests. Treasure Island (FL): StatPearls; 2021.

[41] Koop AC, Thiele ND, Steins D, et al. Therapeutic targeting of myeloperoxidase attenuates NASH in mice. Hepatol Commun. 2020;4(10):1441–1458.

[42] Tutun B, Elbe H, Vardi N, et al. Dexpantenol reduces diabetic nephropathy and renal oxidative stress in rats. Biotech Histochem. 2019;94(2):84–91.

[43] Slyschenkov VS, Rakowska M, Moiseenok AG, et al. Pantethenic acid and its derivatives protect Ehrlich ascites tumor cells against lipid peroxidation. Free Radic Biol Med. 1995;19(6):767–772.

[44] Ye S, Zhou X, Lin J, et al. Asymmetric dimethylarginine induced apoptosis and dysfunction of endothelial progenitor cells: role of endoplasmic reticulum stress pathway. Biomed Res Int. 2017;2017:6395601.